Zacks Investment Research Lowers Tetraphase Pharmaceuticals Inc (TTPH) to Sell
Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
TTPH has been the topic of several other research reports. BMO Capital Markets reaffirmed a “buy” rating and set a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Friday, May 5th. Stifel Nicolaus increased their price objective on Tetraphase Pharmaceuticals from $5.00 to $7.00 and gave the company a “hold” rating in a report on Thursday, March 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $6.85.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 7.23 on Wednesday. The company’s 50-day moving average price is $8.18 and its 200 day moving average price is $5.50. The company’s market capitalization is $272.57 million. Tetraphase Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.19. Tetraphase Pharmaceuticals had a negative return on equity of 39.95% and a negative net margin of 1,120.67%. The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $1.46 million. During the same period last year, the company earned ($0.46) EPS. The firm’s revenue for the quarter was down 24.5% compared to the same quarter last year. On average, equities analysts expect that Tetraphase Pharmaceuticals will post ($2.75) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/10/zacks-investment-research-lowers-tetraphase-pharmaceuticals-inc-ttph-to-sell.html.
In other Tetraphase Pharmaceuticals news, Director L Patrick Gage acquired 11,000 shares of the firm’s stock in a transaction dated Wednesday, March 15th. The stock was purchased at an average price of $7.49 per share, for a total transaction of $82,390.00. Following the acquisition, the director now owns 35,000 shares in the company, valued at approximately $262,150. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.40% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Teza Capital Management LLC raised its position in shares of Tetraphase Pharmaceuticals by 8.9% in the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,281 shares during the period. Federated Investors Inc. PA raised its position in shares of Tetraphase Pharmaceuticals by 1.0% in the fourth quarter. Federated Investors Inc. PA now owns 130,809 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 1,326 shares during the period. Geode Capital Management LLC raised its position in shares of Tetraphase Pharmaceuticals by 0.7% in the first quarter. Geode Capital Management LLC now owns 233,255 shares of the biopharmaceutical company’s stock worth $1,079,000 after buying an additional 1,713 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of Tetraphase Pharmaceuticals by 1.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 113,453 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 1,848 shares during the period. Finally, BlackRock Institutional Trust Company N.A. raised its position in shares of Tetraphase Pharmaceuticals by 0.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 920,408 shares of the biopharmaceutical company’s stock worth $4,261,000 after buying an additional 3,481 shares during the period. Hedge funds and other institutional investors own 55.63% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.